Submit Manuscript  

Article Details


CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy

[ Vol. 15 , Issue. 8 ]

Author(s):

Dandan Tian and Zheyi Hu   Pages 808 - 817 ( 10 )

Abstract:


Cytochromes P450 enzymes, especially CYP3A4, are responsible for metabolizing a broad range of anticancer drugs. Combination therapy is common in patients with cancer, which may cause potential drug drug interactions (DDIs) leading to increased risk of side-effects/toxicity or decreased effectiveness. The review summarizes CYP3A4-mediated DDIs, with anticancer drugs as CYP3A4 substrates or modulators, in clinical trials during cancer therapy and aims to increase clinicians' awareness to take caution to reduce the risk.

Keywords:

Anticancer drugs, cytochromes P450 (CYP) enzymes, drug-drug interactions, pharmacokinetics.

Affiliation:

Department of Clinical Pharmacy, University of Tennessee Health Science Center, College of Pharmacy, 881 Madison Ave., Memphis, TN, 38163, USA.



Read Full-Text article